CA3134382A1 - Classificateurs pour la detection de l'endometriose - Google Patents
Classificateurs pour la detection de l'endometriose Download PDFInfo
- Publication number
- CA3134382A1 CA3134382A1 CA3134382A CA3134382A CA3134382A1 CA 3134382 A1 CA3134382 A1 CA 3134382A1 CA 3134382 A CA3134382 A CA 3134382A CA 3134382 A CA3134382 A CA 3134382A CA 3134382 A1 CA3134382 A1 CA 3134382A1
- Authority
- CA
- Canada
- Prior art keywords
- mir
- endometriosis
- women
- mirna
- machine learning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 443
- 238000001514 detection method Methods 0.000 title abstract description 14
- 108091070501 miRNA Proteins 0.000 claims abstract description 421
- 239000002679 microRNA Substances 0.000 claims abstract description 412
- 238000000034 method Methods 0.000 claims abstract description 325
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 310
- 238000010801 machine learning Methods 0.000 claims abstract description 200
- 239000000523 sample Substances 0.000 claims description 263
- 108091055145 miR-342 stem-loop Proteins 0.000 claims description 187
- 108091032770 miR-451 stem-loop Proteins 0.000 claims description 177
- 108091030646 miR-451a stem-loop Proteins 0.000 claims description 177
- 108091007423 let-7b Proteins 0.000 claims description 167
- 108091065175 miR-3613 stem-loop Proteins 0.000 claims description 167
- 108091091360 miR-125b stem-loop Proteins 0.000 claims description 150
- 230000014509 gene expression Effects 0.000 claims description 129
- 108091046841 MiR-150 Proteins 0.000 claims description 117
- 238000011282 treatment Methods 0.000 claims description 90
- 230000035945 sensitivity Effects 0.000 claims description 63
- 238000007637 random forest analysis Methods 0.000 claims description 55
- 210000001124 body fluid Anatomy 0.000 claims description 52
- 210000002966 serum Anatomy 0.000 claims description 49
- 210000004369 blood Anatomy 0.000 claims description 42
- 239000008280 blood Substances 0.000 claims description 42
- 238000012706 support-vector machine Methods 0.000 claims description 35
- 210000003296 saliva Anatomy 0.000 claims description 31
- 238000012163 sequencing technique Methods 0.000 claims description 30
- 238000012549 training Methods 0.000 claims description 30
- 230000003054 hormonal effect Effects 0.000 claims description 29
- 238000001356 surgical procedure Methods 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 24
- -1 let-713 Proteins 0.000 claims description 24
- 238000003860 storage Methods 0.000 claims description 24
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 20
- 239000000556 agonist Substances 0.000 claims description 20
- 238000003556 assay Methods 0.000 claims description 20
- 238000001794 hormone therapy Methods 0.000 claims description 20
- 210000002381 plasma Anatomy 0.000 claims description 20
- 238000011529 RT qPCR Methods 0.000 claims description 19
- 201000010260 leiomyoma Diseases 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 17
- 108091064282 miR-125 stem-loop Proteins 0.000 claims description 15
- 108091037066 miR-125-1 stem-loop Proteins 0.000 claims description 15
- 108091062107 miR-125-2 stem-loop Proteins 0.000 claims description 15
- 108091079767 miR-125-3 stem-loop Proteins 0.000 claims description 15
- 230000036512 infertility Effects 0.000 claims description 14
- 208000000509 infertility Diseases 0.000 claims description 14
- 230000027758 ovulation cycle Effects 0.000 claims description 14
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 14
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 14
- 238000002357 laparoscopic surgery Methods 0.000 claims description 13
- 108091029227 miR-45-1 stem-loop Proteins 0.000 claims description 13
- 239000002379 progesterone receptor modulator Substances 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 12
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 11
- 231100000535 infertility Toxicity 0.000 claims description 11
- 201000005171 Cystadenoma Diseases 0.000 claims description 10
- 206010050697 Fallopian tube cyst Diseases 0.000 claims description 10
- 239000003098 androgen Substances 0.000 claims description 10
- 108091059434 miR-45 stem-loop Proteins 0.000 claims description 10
- 108091085809 miR-45-2 stem-loop Proteins 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 9
- 206010043276 Teratoma Diseases 0.000 claims description 9
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 9
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 9
- 229960005489 paracetamol Drugs 0.000 claims description 9
- 206010058674 Pelvic Infection Diseases 0.000 claims description 8
- 229940111134 coxibs Drugs 0.000 claims description 8
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 8
- 229940127234 oral contraceptive Drugs 0.000 claims description 8
- 239000003539 oral contraceptive agent Substances 0.000 claims description 8
- 239000000583 progesterone congener Substances 0.000 claims description 8
- 230000003623 progesteronic effect Effects 0.000 claims description 8
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 7
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 7
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 7
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 7
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 7
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 7
- 229960005370 atorvastatin Drugs 0.000 claims description 7
- 230000000740 bleeding effect Effects 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229960003765 fluvastatin Drugs 0.000 claims description 7
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims description 7
- 229960004844 lovastatin Drugs 0.000 claims description 7
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 7
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 7
- 229950009116 mevastatin Drugs 0.000 claims description 7
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 7
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 7
- 238000002493 microarray Methods 0.000 claims description 7
- 229960002797 pitavastatin Drugs 0.000 claims description 7
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 7
- 229960002965 pravastatin Drugs 0.000 claims description 7
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 7
- 229960000672 rosuvastatin Drugs 0.000 claims description 7
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 7
- 229960002855 simvastatin Drugs 0.000 claims description 7
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 7
- 239000003418 antiprogestin Substances 0.000 claims description 6
- 229960005110 cerivastatin Drugs 0.000 claims description 6
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 6
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 238000003753 real-time PCR Methods 0.000 claims description 6
- 208000004998 Abdominal Pain Diseases 0.000 claims description 5
- 206010000059 abdominal discomfort Diseases 0.000 claims description 5
- 231100000319 bleeding Toxicity 0.000 claims description 5
- 230000036210 malignancy Effects 0.000 claims description 5
- 231100000536 menstrual disturbance Toxicity 0.000 claims description 5
- 238000007481 next generation sequencing Methods 0.000 claims description 5
- 208000037062 Polyps Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 210000001808 exosome Anatomy 0.000 claims description 3
- 229940124638 COX inhibitor Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 37
- 238000012545 processing Methods 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 201000010099 disease Diseases 0.000 description 28
- 229920002477 rna polymer Polymers 0.000 description 23
- 239000000090 biomarker Substances 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 238000013459 approach Methods 0.000 description 18
- 238000004590 computer program Methods 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 230000002175 menstrual effect Effects 0.000 description 15
- 108700012941 GNRH1 Proteins 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000007170 pathology Effects 0.000 description 13
- 108091084619 miR-125b-1 stem-loop Proteins 0.000 description 11
- 108091063409 miR-125b-2 stem-loop Proteins 0.000 description 11
- 108091050014 miR-125b-3 stem-loop Proteins 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 108700011259 MicroRNAs Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000007477 logistic regression Methods 0.000 description 8
- 108091090860 miR-150 stem-loop Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 108091050724 let-7b stem-loop Proteins 0.000 description 7
- 108091027963 non-coding RNA Proteins 0.000 description 7
- 102000042567 non-coding RNA Human genes 0.000 description 7
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 7
- 229960003387 progesterone Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 6
- HEAUOKZIVMZVQL-VWLOTQADSA-N Elagolix Chemical compound COC1=CC=CC(C=2C(N(C[C@H](NCCCC(O)=O)C=3C=CC=CC=3)C(=O)N(CC=3C(=CC=CC=3F)C(F)(F)F)C=2C)=O)=C1F HEAUOKZIVMZVQL-VWLOTQADSA-N 0.000 description 6
- 206010046798 Uterine leiomyoma Diseases 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 239000003886 aromatase inhibitor Substances 0.000 description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
- 208000031513 cyst Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 108091023663 let-7 stem-loop Proteins 0.000 description 6
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 6
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 229940046844 aromatase inhibitors Drugs 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 229940125697 hormonal agent Drugs 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 108091056875 miR-1256 stem-loop Proteins 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000039471 Small Nuclear RNA Human genes 0.000 description 4
- 102000039634 Untranslated RNA Human genes 0.000 description 4
- 108020004417 Untranslated RNA Proteins 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 229960000766 danazol Drugs 0.000 description 4
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 4
- 229950004823 elagolix Drugs 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108010037003 Buserelin Proteins 0.000 description 3
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 3
- 108010069236 Goserelin Proteins 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 108010021717 Nafarelin Proteins 0.000 description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
- 208000000450 Pelvic Pain Diseases 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002719 buserelin Drugs 0.000 description 3
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 3
- 229960004126 codeine Drugs 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 229960005408 deslorelin Drugs 0.000 description 3
- 108700025485 deslorelin Proteins 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 108700020746 histrelin Proteins 0.000 description 3
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 3
- 229960002193 histrelin Drugs 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- 238000009802 hysterectomy Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 229960002333 nafarelin Drugs 0.000 description 3
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 229960002085 oxycodone Drugs 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 210000001138 tear Anatomy 0.000 description 3
- 229960004824 triptorelin Drugs 0.000 description 3
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 3
- 229920001621 AMOLED Polymers 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 206010058897 Adnexa uteri mass Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013145 classification model Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004883 computer application Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007847 digital PCR Methods 0.000 description 2
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
- 229960004913 dydrogesterone Drugs 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960004761 gestrinone Drugs 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108091041305 miR2613 stem-loop Proteins 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 229940110234 mirena Drugs 0.000 description 2
- 238000011201 multiple comparisons test Methods 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000010979 ruby Substances 0.000 description 2
- 229910001750 ruby Inorganic materials 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000005893 serous cystadenoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 2
- 229960001023 tibolone Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XGWIJUOSCAQSSV-XHDPSFHLSA-N (S,S)-hexythiazox Chemical compound S([C@H]([C@@H]1C)C=2C=CC(Cl)=CC=2)C(=O)N1C(=O)NC1CCCCC1 XGWIJUOSCAQSSV-XHDPSFHLSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102000007269 CA-125 Antigen Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091007413 Extracellular RNA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 108091007772 MIRLET7C Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 108091027766 Mir-143 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 206010054827 Peritoneal lesion Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 238000012274 Preoperative evaluation Methods 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 101150018082 U6 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000002595 endometriosis of ovary Diseases 0.000 description 1
- 238000007636 ensemble learning method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108091091807 let-7a stem-loop Proteins 0.000 description 1
- 108091057746 let-7a-4 stem-loop Proteins 0.000 description 1
- 108091028376 let-7a-5 stem-loop Proteins 0.000 description 1
- 108091024393 let-7a-6 stem-loop Proteins 0.000 description 1
- 108091091174 let-7a-7 stem-loop Proteins 0.000 description 1
- 108091030917 let-7b-1 stem-loop Proteins 0.000 description 1
- 108091082924 let-7b-2 stem-loop Proteins 0.000 description 1
- 108091033753 let-7d stem-loop Proteins 0.000 description 1
- 108091024449 let-7e stem-loop Proteins 0.000 description 1
- 108091044227 let-7e-1 stem-loop Proteins 0.000 description 1
- 108091071181 let-7e-2 stem-loop Proteins 0.000 description 1
- 108091063986 let-7f stem-loop Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091045872 miR-135 stem-loop Proteins 0.000 description 1
- 108091026523 miR-135a stem-loop Proteins 0.000 description 1
- 108091026375 miR-135b stem-loop Proteins 0.000 description 1
- 108091086065 miR-135b-2 stem-loop Proteins 0.000 description 1
- 108091041042 miR-18 stem-loop Proteins 0.000 description 1
- 108091062221 miR-18a stem-loop Proteins 0.000 description 1
- 108091065201 miR-341 stem-loop Proteins 0.000 description 1
- 108091043157 miR-500a stem-loop Proteins 0.000 description 1
- 108091049400 miR-6755 stem-loop Proteins 0.000 description 1
- 108091024443 miRa-135-1 stem-loop Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004707 mucinous cystadenoma Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000013433 optimization analysis Methods 0.000 description 1
- 239000003217 oral combined contraceptive Substances 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 208000030747 ovarian endometriosis Diseases 0.000 description 1
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004223 overdiagnosis Methods 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003045 statistical classification method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
- G06F18/213—Feature extraction, e.g. by transforming the feature space; Summarisation; Mappings, e.g. subspace methods
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
- G06F18/217—Validation; Performance evaluation; Active pattern learning techniques
- G06F18/2193—Validation; Performance evaluation; Active pattern learning techniques based on specific statistical tests
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
- G06N20/20—Ensemble learning
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/24—Classification techniques
- G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
- G06F18/2411—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on the proximity to a decision surface, e.g. support vector machines
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/24—Classification techniques
- G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
- G06F18/2413—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
- G06F18/24147—Distances to closest patterns, e.g. nearest neighbour classification
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/24—Classification techniques
- G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
- G06F18/2415—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on parametric or probabilistic models, e.g. based on likelihood ratio or false acceptance rate versus a false rejection rate
- G06F18/24155—Bayesian classification
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/24—Classification techniques
- G06F18/243—Classification techniques relating to the number of classes
- G06F18/24323—Tree-organised classifiers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
Landscapes
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Biology (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Bioinformatics & Computational Biology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pathology (AREA)
- Mathematical Physics (AREA)
- Computing Systems (AREA)
- Bioethics (AREA)
- Probability & Statistics with Applications (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des procédés améliorés pour la détection de l'endométriose. De manière générale, les procédés comprennent, sans y être limités, l'application d'un algorithme d'apprentissage automatique à des niveaux de miARN afin de détecter, prédire, diagnostiquer ou surveiller la présence ou l'absence d'endométriose.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840300P | 2019-04-29 | 2019-04-29 | |
US62/840,300 | 2019-04-29 | ||
USPCT/US2019/059006 | 2019-10-31 | ||
PCT/US2019/059006 WO2020092672A2 (fr) | 2018-10-31 | 2019-10-31 | Algorithme quantitatif pour endométriose |
PCT/US2020/030284 WO2020223238A1 (fr) | 2019-04-29 | 2020-04-28 | Classificateurs pour la détection de l'endométriose |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3134382A1 true CA3134382A1 (fr) | 2020-11-05 |
Family
ID=73028712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3134382A Pending CA3134382A1 (fr) | 2019-04-29 | 2020-04-28 | Classificateurs pour la detection de l'endometriose |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3963094A4 (fr) |
JP (1) | JP2022530636A (fr) |
CN (1) | CN114402083A (fr) |
AU (1) | AU2020265577A1 (fr) |
BR (1) | BR112021021866A2 (fr) |
CA (1) | CA3134382A1 (fr) |
SG (1) | SG11202111117WA (fr) |
WO (1) | WO2020223238A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015148919A2 (fr) | 2014-03-27 | 2015-10-01 | Yale University | Micro-arn circulants en tant que biomarqueurs pour l'endométriose |
CA3035429A1 (fr) | 2016-08-30 | 2018-03-08 | Yale University | Micro-arn servant de biomarqueurs de l'endometriose |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403489D0 (en) * | 2014-02-27 | 2014-04-16 | Univ London Queen Mary | Biomarkers for endometriosis |
EP3676395A4 (fr) * | 2017-08-30 | 2021-09-01 | Dot Laboratories, Inc. | Méthodes et compositions de détection et de traitement de l'endométriose |
WO2020092672A2 (fr) * | 2018-10-31 | 2020-05-07 | Yale University | Algorithme quantitatif pour endométriose |
-
2020
- 2020-04-28 CA CA3134382A patent/CA3134382A1/fr active Pending
- 2020-04-28 JP JP2021564296A patent/JP2022530636A/ja active Pending
- 2020-04-28 EP EP20799450.0A patent/EP3963094A4/fr active Pending
- 2020-04-28 CN CN202080047981.9A patent/CN114402083A/zh active Pending
- 2020-04-28 SG SG11202111117WA patent/SG11202111117WA/en unknown
- 2020-04-28 BR BR112021021866A patent/BR112021021866A2/pt not_active Application Discontinuation
- 2020-04-28 WO PCT/US2020/030284 patent/WO2020223238A1/fr unknown
- 2020-04-28 AU AU2020265577A patent/AU2020265577A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3963094A4 (fr) | 2024-02-28 |
BR112021021866A2 (pt) | 2021-12-21 |
EP3963094A1 (fr) | 2022-03-09 |
WO2020223238A1 (fr) | 2020-11-05 |
CN114402083A (zh) | 2022-04-26 |
JP2022530636A (ja) | 2022-06-30 |
SG11202111117WA (en) | 2021-11-29 |
AU2020265577A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230059244A1 (en) | Classifiers for detection of endometriosis | |
JP6775499B2 (ja) | 肺がん状態の評価方法 | |
US20220305075A1 (en) | Methods and compositions for detecting and treating endometriosis | |
JP2022519897A (ja) | 対象の妊娠関連状態を決定するための方法及びシステム | |
US11685951B2 (en) | Biomarkers for intracranial aneurysm | |
US20210158894A1 (en) | Processes for Genetic and Clinical Data Evaluation and Classification of Complex Human Traits | |
CN109477145A (zh) | 炎症性肠病的生物标志物 | |
JP2023524627A (ja) | 核酸のメチル化分析による結腸直腸癌を検出するための方法およびシステム | |
US20230348980A1 (en) | Systems and methods of detecting a risk of alzheimer's disease using a circulating-free mrna profiling assay | |
CA3134382A1 (fr) | Classificateurs pour la detection de l'endometriose | |
EP3146077A1 (fr) | Signatures moléculaires de tissu de rejets de transplantation hépatique | |
WO2022051245A2 (fr) | Méthodes et systèmes de prédiction de la réponse à des thérapies anti-tnf | |
JP2024512490A (ja) | 患者を分類かつ治療する方法 | |
CA3163904A1 (fr) | Techniques d'apprentissage automatique pour analyse d'expression genique | |
EP3790987A1 (fr) | Classificateurs à l'échelle du génome pour détecter un rejet de greffe subaigu et d'autres conditions de transplantation | |
AU2015263998A1 (en) | Gene expression profiles associated with sub-clinical kidney transplant rejection | |
JP2021517892A (ja) | 疼痛のための精密医療:診断バイオマーカー、薬理ゲノミクス、およびリパーパス薬 | |
CN114134228B (zh) | 评估PI3K/Akt/mTOR通路相关基因突变的试剂盒、系统、储存介质及其应用 | |
WO2024118630A2 (fr) | Méthodes et modèles de récidive post-opératoire de la maladie de crohn | |
Fong et al. | Rapid Exome Sequencing for Critically Ill Children: Implementation and Challenges in the Asian Context | |
WO2022120076A1 (fr) | Classificateurs cliniques et classificateurs génomiques et leurs utilisations | |
WO2022245773A2 (fr) | Procédés et systèmes de profilage de méthylation d'états liés à la grossesse |